December 14, 2020
A new drug discovered through a research collaboration between the University at Buffalo and Tetra Therapeutics took a major step toward becoming a first-in-class treatment for Fragile X Syndrome, a leading genetic cause of autism. The drug, BPN14770, achieved positive topline results in phase 2 clinical study. The innovative treatment […]